Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros, Inc. (Nasdaq: NEPH) is a water technology company focused on filtration products, services, and water-quality education for medical, healthcare, commercial, and industrial markets. The NEPH news feed highlights how the company’s filtration solutions and educational initiatives are applied in practice, as well as how its financial performance evolves over time.
News about Nephros often includes quarterly and year-to-date financial results, where the company reports net revenue, net income or loss, gross margin, and adjusted EBITDA. These updates frequently discuss programmatic revenue tied to recurring filter use, emergency response sales related to compromised water events, and trends in service revenue. Investors can use these releases to understand how Nephros’ programmatic business and active customer sites are developing across infection control, dialysis water, and commercial segments.
The NEPH news stream also covers product launches and technology developments. Examples include new filtration products designed to support compliance with water quality standards and to extend Nephros’ technology into additional medical, commercial, and industrial applications. These announcements explain how new offerings fit within the company’s portfolio and which types of facilities or industries they are intended to serve.
Another recurring theme in Nephros news is water safety education. The company reports on webinars, speaking engagements, and the activities of the Nephros Water Institute, which provides regulatory and risk-based educational programming for professionals responsible for water systems. Together, these financial, product, and educational updates give a rounded view of Nephros’ operations and strategic focus. Users interested in NEPH can review this page regularly for the latest company-issued press releases and related disclosures.
Nephros reported a 43% increase in net revenue, reaching $2.5 million for Q1 2020, up from $1.8 million in Q1 2019. The company's net loss improved by 19%, totaling $1.1 million. Adjusted EBITDA showed a 7% improvement, at ($0.8 million). Gross margins increased to 59% from 56%. R&D expenses decreased by 26% to $0.6 million, while SG&A expenses rose by 30%, totaling $1.9 million. Nephros held $9.0 million in cash and equivalents as of March 31, 2020.
Summary not available.